Sorafenib in locally advanced or metastatic breast cancer

Expert Opinion on Investigational Drugs

Volumn 21, Issue 8, 2012, Pages 1177-1191

  Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

anti angiogenic; anti proliferative; metastatic breast cancer; multikinase inhibitor; sorafenib

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; GEMCITABINE; LETROZOLE; PACLITAXEL; PLACEBO; PLATELET DERIVED GROWTH FACTOR A; RAF PROTEIN; SORAFENIB;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; COUGHING; DESQUAMATION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOTENSION; LIVER FAILURE; MALARIA; MENINGITIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SEPSIS; SIDE EFFECT; WOUND INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FLUOROURACIL; HUMANS; NITRILES; PACLITAXEL; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; TAXOIDS; TRIAZOLES;

EID: 84863649779     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.689824     Document Type: Review

References (80)

1. World Health Organization. Cancer Fact Sheet No. 297: WHO; 2011
2. Barton S, Swanton C. Recent developments in treatment stratification for metastatic breast cancer. Drugs 2011;71:2099-113
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. NCCN; Washington: 2011
4. Cardoso F, Fallowfield L, Costa A, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi25-30
5. Jensen HM, Chen I, DeVault MR, et al. Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science 1982;218:293-5 (Pubitemid 12030603)
6. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23:1782-90 (Pubitemid 46211430)
7. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994;54:6504-11
8. Chan A. Antiangiogenic therapy for metastatic breast cancer: current status and future directions. Drugs 2009;69:167-81
9. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24 (Pubitemid 37433402)
10. Bianchi G, Loibl S, Zamagni C, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anti Cancer Drugs 2009;20:616-24 Single-agent use of sorafenib in metastatic breast cancer.
11. Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: north Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009;27:11-15
12. Treatment Group and Mayo Clinic Trial N0336. J Clin Oncology 2009;27:11-15. Single-agent use of sorafenib in metastatic breast cancer.
13. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76 First Phase III study to demonstrate a PFS benefit with an anti-angiogenic agent in combination with chemotherapy.
14. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47
15. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29:4286-93
16. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60
17. Tanne JH. FDA cancels approval for bevacizumab in advanced breast cancer. BMJ 2011;343:d7684
18. Burstein HJ. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol 2011;29:1232-5
19. Pollack A. F.D.A. Revokes approval of avastin for use as breast cancer drug. Ny Times. November 19, 2011
20. European Medicines Agency. EPAR summary for the public: Avastin. Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR--- Summary-for-the-public/human/ 000582/WC500029260.pdf [Accessed 16 November 2011]
21. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15:422-32 (Pubitemid 351472408)
22. Sartore-Bianchi A, Ricotta R, Cerea G, et al. Rationale and clinical results of multi-target treatments in oncology. Int J Biol Markers 2007;22:S77-87 (Pubitemid 46730026)
23. Ding Q, Huo L, Yang JY, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 2008;68:6109-17
24. Merz M, Komljenovic D, Zwick S, et al. Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. Eur J Cancer 2011;47:277-86
25. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34 (Pubitemid 46089673)
26. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
27. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008;13:845-58
28. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61:535-48
29. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109 (Pubitemid 39331023)
30. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40 Overview of the mechanism of action for sorafenib.
31. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37 (Pubitemid 46698720)
32. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561-74 (Pubitemid 46295136)
33. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8 (Pubitemid 46094197)
34. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861-9 (Pubitemid 41509409)
35. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-5
36. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300 (Pubitemid 46630787)
37. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61 (Pubitemid 40826133)
38. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-80 (Pubitemid 41060823)
39. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94 (Pubitemid 41510145)
40. Strumberg D, Voliotis D, Moeller JG, et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002;40:580-1
41. Awada A, Gil T, Whenham N, et al. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. J Clin Pharmacol 2011;51:1674-84
42. Bonelli MA, Fumarola C, Alfieri RR, et al. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat 2010;124:79-88
43. Richly H, Henning BF, Kupsch P, et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-73
44. Awada A, Gil T, Whenham N, et al. Phase I trial to evaluate safety, pharmacokinetics, and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors [abstract 401]. Ann Oncol 2007;18(Suppl):iv39
45. Bunone G, Briand PA, Miksicek RJ, et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-83 (Pubitemid 26141134)
46. Isaacs C, Herbolsheimer P, Liu MC, et al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 2011;125:137-43
47. Baselga J, Segalla JGM, Roche H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012; Epub ahead of print Complete analysis of the SOLTI-0701 TIES study.
48. Gradishar W, Kaklamani V, Prasad Sahoo T, et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC) [abstract 44]. Abstract and oral presentation at the 32nd Annual San Antonio Breast Cancer Symposium; Dec 9 - 13, 2009; San Antonio, TX Primary analysis of the NU07B1 TIES study.
49. Hudis C, Tauer KW, Hermann RC, et al. Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV) [abstract 1009]. Abstract and oral presentation at the annual meeting of the American Society of Clinical Oncology; June 3 - 7, 2011; Chicago, IL Primary analysis of the AC01B07 TIES study.
50. Mariani G, Burdaeva O, Roman L, et al. A double-blind, randomized phase IIb study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer: FM-B07-01 Trial [abstract 17LBA]. Abstract and oral presentation at the European Multidisciplinary Congress; Sept 23 - 27, 2011; Stockholm, Sweden Primary analysis of the FM-B07-01 TIES study.
51. Gradishar W, Dalenc F, Kaklamani V, et al. Multivariate analysis of progression-free survival in 2 phase 2b, multinational, double-blind, randomized, placebo-controlled trials evaluating sorafenib plus standard chemotherapy in patients with HER2-negative locally advanced or metastatic breast cancer [abstract 1073]. Abstract and poster presentation at the annual meeting of the American Society of Clinical Oncology; June 4 - 8, 2010; Chicago, IL
52. Bondarde S, Kaklamani V, Prasad Sahoo T, et al. Sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer: overall survival results from a double-blind, randomized, placebo-controlled, phase 2b trial [abstract P2-16-03]. Abstract and poster presentation at the 33rd Annual San Antonio Breast Cancer Symposium; Dec 8 - 12, 2010; San Antonio, TX Overall survival and updated safety and tolerability data for the NU07B01 study.
53. Sahoo TP, Kaklamani V, Lokanatha D, et al. A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase 2b study evaluating sorafenib with paclitaxel in patients with advanced breast cancer [abstract 1114]. Abstract and poster presentation at the annual meeting of the American Society of Clinical Oncology; June 4 - 8, 2010; Chicago, IL Subgroup analysis of NU07B01 study that presents efficacy and safety data for patients enrolled in India and patients enrolled in the United States and Brazil, important to consider in view of the expanding clinical trial programs.
54. Agarwal G, Pradeep PV, Aggarwal V, et al. Spectrum of breast cancer in Asian women. World J Surg 2007;31:1031-40 (Pubitemid 46716756)
55. Agarwal G, Ramakant P. Breast cancer care in India: the current scenario and the challenges for the future. Breast Care 2008;3:21-7 (Pubitemid 351365649)
56. Chopra R. The Indian scene. J Clin Oncol 2001;19:106S-11S (Pubitemid 32880092)
57. Huggins RH, Kuzel TM, Anderson RT, et al. Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: impact on quality of life (QoL). J Clin Oncol 2008;26:abstract 16122
58. Baselga J, Schwartzberg L, Petrenciuc O, et al. Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC) [abstract TPS124]. Abstract and poster presentation at the annual meeting of the American Society of Clinical Oncology; June 3 - 7, 2011; Chicago, IL Study design of the Phase III confirmatory trial based on results from the SOLTI-0701 TIES study.
59. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21 (Pubitemid 44511625)
60. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8
61. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81-6; discussion 86
62. Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast 2011;20:S56-60
63. U.S. Department of Health and Human Services. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2007
64. Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011;29:2439-42
65. Buyse M, Sargent DJ, Saad ED. Survival is not a good outcome for randomized trials with effective subsequent therapies. J Clin Oncol 2011;29:4719-20
66. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21
67. Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011;29:83-8
68. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9 (Pubitemid 46224178)
69. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-23
70. Saad ED, Katz A, Hoff PM, et al. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010;21:7-12
71. D'Agostino RB Sr. Changing end points in breast-cancer drug approval - the Avastin story. N Engl J Med 2011;365:e2
72. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008;13:19-21
73. Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity [corrected]. Nat Rev Clin Oncol 2010;7:139-47
74. Alsina M, Ruiz-Echarri M, Capdevila J, et al. Biomarkers for therapies directed at angiogenesis. Curr Colorectal Cancer Rep 2010;6:133-43
75. Gianni L, Romieu G, Lichinitser M, et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) [abstract S4-8]. Cancer Res 2011;71:109s
76. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366(4):310-20
77. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012;366(4):299-309
78. Spigel DR, Hainsworth JD, Burris HA III, et al. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. Clin Adv Hematol Oncol 2011;9:280-6
79. Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008;19:212-22 (Pubitemid 351201700)
80. Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 2011;16:1508-19 In-depth review of hand-foot skin reaction during the TIES studies with guidance for mitigation.